Technical Analysis for INSYQ - Insys Therapeutics Inc

Grade Last Price % Change Price Change
grade D 0.0649 12.28% 0.0071
INSYQ closed up 12.28 percent on Friday, December 6, 2019, on 1.52 times normal volume.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical INSYQ trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish 12.28%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 12.28%
Stochastic Reached Oversold Weakness 12.28%
Wide Bands Range Expansion 12.28%
Oversold Stochastic Weakness 12.28%
20 DMA Resistance Bearish -13.47%
Pocket Pivot Bullish Swing Setup -13.47%

Older signals for INSYQ ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. On June 10, 2019, INSYS Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
RTT Euphoriants Drugs Pharmaceutical Pain Organic Compounds U.S. Bankruptcy Court Chemotherapy Drug Delivery U.S. Bankruptcy Court For The District Of Delaware Analgesics Morphinans Opioids Vomiting Drug Delivery Systems Glioblastoma Multiforme Aids Chemotherapy Induced Nausea Fentanyl Allergic Reactions Dronabinol

Is INSYQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.344
52 Week Low 0.03
Average Volume 147,160
200-Day Moving Average 0.0000
50-Day Moving Average 0.1001
20-Day Moving Average 0.0712
10-Day Moving Average 0.0641
Average True Range 0.0207
ADX 8.83
+DI 17.2260
-DI 16.3356
Chandelier Exit (Long, 3 ATRs ) 0.0604
Chandelier Exit (Short, 3 ATRs ) 0.1141
Upper Bollinger Band 0.0918
Lower Bollinger Band 0.0506
Percent B (%b) 0.35
BandWidth 57.8652
MACD Line -0.0110
MACD Signal Line -0.0121
MACD Histogram 0.0011
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0997
Resistance 3 (R3) 0.0993 0.0872 0.0939
Resistance 2 (R2) 0.0872 0.0784 0.0875 0.0920
Resistance 1 (R1) 0.0761 0.0729 0.0817 0.0765 0.0900
Pivot Point 0.0640 0.0640 0.0668 0.0643 0.0640
Support 1 (S1) 0.0529 0.0552 0.0585 0.0533 0.0398
Support 2 (S2) 0.0408 0.0497 0.0411 0.0378
Support 3 (S3) 0.0297 0.0408 0.0359
Support 4 (S4) 0.0301